Literature DB >> 16988013

Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids.

Joanna E Chivers1, Wei Gong, Elizabeth M King, Joachim Seybold, Judith C Mak, Louise E Donnelly, Neil S Holden, Robert Newton.   

Abstract

Although repression of inflammatory gene expression makes glucocorticoids powerful anti-inflammatory agents, side effects limit usage and drive the search for improved glucocorticoid receptor (GR) ligands. In A549 pulmonary cells, dexamethasone and the prototypical dissociated ligand RU24858 (Mol Endocrinol 11:1245-1255, 1997) repress interleukin (IL)-1beta-induced expression of cyclooxygenase (COX)-2 and IL-8. Although RU24858 is a weaker GR ligand, both glucocorticoids showed similar efficacies on transrepression of nuclear factor kappaB (NF-kappaB)-dependent transcription, whereas RU24858 yielded less than 12% of the response to dexamethasone on a classic glucocorticoid response element (GRE) reporter (transactivation). Modest NF-kappaB-dependent transrepression ( approximately 40%), along with analysis of IL-8 transcription rate and the accumulation of unspliced nuclear RNA, indicates that transrepression does not fully account for the repression of genes such as IL-8. This was confirmed by the finding that mRNA degradation is increased by both dexamethasone and RU24858. Analysis of IL-1beta-induced steady-state mRNA levels for IL-8 and COX-2 show that dexamethasone- and RU24858-dependent repression of these genes is attenuated by inhibitors of transcription and protein synthesis. Because similar effects were observed with respect to COX-2 and IL-8 protein expression, we conclude that glucocorticoid-dependent gene expression is necessary for repression by both glucocorticoids. Despite RU24858 being defective at classic GRE-dependent transactivation, both dexamethasone and RU24858 induced the expression of potentially anti-inflammatory genes and metabolic genes, suggesting the importance of nontraditional glucocorticoid-dependent gene expression. Thus, classic transactivation- and transrepressionbased screens for anti-inflammatory "dissociated" GR ligands may be flawed because they may not reflect the effects on real glucocorticoid-inducible genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988013     DOI: 10.1124/mol.106.025841

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

1.  Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.

Authors:  N S Holden; C F Rider; M J Bell; J Velayudhan; E M King; M Kaur; M Salmon; M A Giembycz; R Newton
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 2.  Minireview: latest perspectives on antiinflammatory actions of glucocorticoids.

Authors:  Karolien De Bosscher; Guy Haegeman
Journal:  Mol Endocrinol       Date:  2008-12-18

Review 3.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 4.  Glucocorticoid and cytokine crosstalk: Feedback, feedforward, and co-regulatory interactions determine repression or resistance.

Authors:  Robert Newton; Suharsh Shah; Mohammed O Altonsy; Antony N Gerber
Journal:  J Biol Chem       Date:  2017-03-10       Impact factor: 5.157

Review 5.  Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Authors:  Robert Newton; Mark A Giembycz
Journal:  Br J Pharmacol       Date:  2016-11-09       Impact factor: 8.739

6.  Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide.

Authors:  M M Kelly; E M King; C F Rider; C Gwozd; N S Holden; J Eddleston; B Zuraw; R Leigh; P M O'Byrne; R Newton
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids.

Authors:  Neil S Holden; Matthew J Bell; Christopher F Rider; Elizabeth M King; David D Gaunt; Richard Leigh; Malcolm Johnson; David P Siderovski; Scott P Heximer; Mark A Giembycz; Robert Newton
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-11       Impact factor: 11.205

8.  Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence.

Authors:  Carmen R Tchen; Joana R S Martins; Nasren Paktiawal; Roberta Perelli; Jeremy Saklatvala; Andrew R Clark
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

9.  Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects.

Authors:  Andreas R Baudy; Erica K M Reeves; Jesse M Damsker; Christopher Heier; Lindsay M Garvin; Blythe C Dillingham; John McCall; Sree Rayavarapu; Zuyi Wang; Jack H Vandermeulen; Arpana Sali; Vanessa Jahnke; Stephanie Duguez; Debra DuBois; Mary C Rose; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

10.  Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK.

Authors:  Elizabeth M King; Neil S Holden; Wei Gong; Christopher F Rider; Robert Newton
Journal:  J Biol Chem       Date:  2009-07-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.